Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer

In this issue of The Oncologist, Agarwal et al. report negative results from a phase I trial of LFA102. Although “negative” in terms of antitumor activity, the study provides useful pharmacokinetic and pharmacodynamic information. Future trials evaluating PRLR blockers alone and in combination with...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Sullivan, Ciara C., Bates, Susan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861375/
https://www.ncbi.nlm.nih.gov/pubmed/27107001
http://dx.doi.org/10.1634/theoncologist.2016-0108
Descripción
Sumario:In this issue of The Oncologist, Agarwal et al. report negative results from a phase I trial of LFA102. Although “negative” in terms of antitumor activity, the study provides useful pharmacokinetic and pharmacodynamic information. Future trials evaluating PRLR blockers alone and in combination with other agents may still be warranted in patients with breast and prostate cancer.

Ejemplares similares